NEJ026: phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations
M Maemondo, T Fukuhara, S Sugawara… - Annals of …, 2016 - annalsofoncology.org
Background Development of treatment for EGFR-mutated non-small-cell lung cancer
(NSCLC) had been focused on monotherapy of gefitinib, erlotinib, or afatinib. However …
(NSCLC) had been focused on monotherapy of gefitinib, erlotinib, or afatinib. However …
Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026.
N Furuya, T Fukuhara, H Saito, K Watanabe… - 2018 - ascopubs.org
9006 Background: Development of treatment for EGFR-mutated non-small-cell lung cancer
(NSCLC) had been focused on monotherapy of gefitinib, erlotinib, or afatinib. Combinations …
(NSCLC) had been focused on monotherapy of gefitinib, erlotinib, or afatinib. Combinations …
[HTML][HTML] Phase III study comparing bevacizumab plus erlotinib (BE) to erlotinib (E) in patients (pts) with untreated NSCLC harboring EGFR mutations: NEJ026
Y Kawashima, T Fukuhara, N Furuya… - Annals of …, 2018 - annalsofoncology.org
Background: Combinations of EGFR-TKIs and VEGF inhibitors are one of the candidates for
next strategy for EGFR-mutated lung cancer. We conducted a phase III study comparing BE …
next strategy for EGFR-mutated lung cancer. We conducted a phase III study comparing BE …
NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations.
M Maemondo, T Fukuhara, H Saito, N Furuya… - 2020 - ascopubs.org
9506 Background: In NEJ026, a phase III trial comparing bevacizumab plus erlotinib (BE) to
erlotinib monotherapy (E) for EGFR-mutated non-small-cell lung cancer (NSCLC), we …
erlotinib monotherapy (E) for EGFR-mutated non-small-cell lung cancer (NSCLC), we …
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567) …
T Seto, T Kato, M Nishio, K Goto, S Atagi… - The lancet …, 2014 - thelancet.com
Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with
activating EGFR mutation-positive non-small-cell lung cancer (NSCLC), median progression …
activating EGFR mutation-positive non-small-cell lung cancer (NSCLC), median progression …
Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive nonsquamous non-small cell lung cancer …
T Kato, T Seto, M Nishio, K Goto, S Atagi, Y Hosomi… - 2014 - ascopubs.org
8005 Background: Despite the development of EGFR tyrosine kinase inhibitors, median
progression-free survival (PFS) is only about 13 months in patients with EGFR mutation …
progression-free survival (PFS) is only about 13 months in patients with EGFR mutation …
[HTML][HTML] Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutations …
K Yoshida, Y Yamada - Translational Lung Cancer Research, 2015 - ncbi.nlm.nih.gov
© Translational lung cancer research. All rights reserved. Transl Lung Cancer Res 2015; 4
(3): 217-219 www. tlcr. org patients with advanced NSCLC harboring EGFR-activating has …
(3): 217-219 www. tlcr. org patients with advanced NSCLC harboring EGFR-activating has …
BEVERLY: rationale and design of a randomized open-label phase III trial comparing bevacizumab plus erlotinib versus erlotinib alone as first-line treatment of …
C Gridelli, A Rossi, F Ciardiello, F De Marinis… - Clinical Lung Cancer, 2016 - Elsevier
Background About 20% of advanced non–small-cell lung cancer (NSCLC) cases harbor
somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor …
somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor …
[HTML][HTML] Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer …
N Yamamoto, T Seto, M Nishio, K Goto, I Okamoto… - Lung Cancer, 2021 - Elsevier
Abstract Objectives The JO25567 randomized Phase II study demonstrated a statistically
significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared …
significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared …
Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer …
N Yamamoto, T Seto, M Nishio, K Goto, I Okamoto… - 2018 - ascopubs.org
9007 Background: In JO25567 (Clinical trials registry number. JapicCTI-111390), EB
significantly prolonged progression-free survival (PFS) in patients with NSCLC with …
significantly prolonged progression-free survival (PFS) in patients with NSCLC with …
相关搜索
- egfr mutations untreated nsclc
- egfr mutations erlotinib in patients
- erlotinib in patients untreated nsclc
- egfr mutations survival analysis
- survival analysis nsclc patients
- egfr mutation lung cancer
- egfr mutation open label
- egfr mutations nsclc patients
- egfr mutation erlotinib alone
- egfr mutations erlotinib treatment
- erlotinib treatment nsclc patients